Please assess the completion status of the following clinical trial:

Trial Title: Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent for participation of the study, given before undergoing any study-specific procedures~2. Clinical history compatible with type 1 diabetes diagnosed less than 2 years before enrolment~3. In the first part of the study patients 1-9 only male patients between 18-40 years of age will be included. In the second part of the study, patients 10-24, both male and female patients 18 to 40 years of age (inclusive at both ends) will be included.~4. Mentally stable and, in the opinion of the investigator, able to comply with the procedures of the study protocol~5. Fasting plasma C-peptide concentration \>0.12 nmol/L.~6. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, if they are using effective methods of contraception during the study. Acceptable birth control methods are those with a failure rate of less than 1% per year when used consistently and correctly. Such methods include (in Recommendations related to contraception and pregnancy testing in clinical trials, supplied from www.hma.eu/):~   1. Combined (estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation.~      * oral~     * intravaginal~     * transdermal~  2. progestogen-only hormonal contracption associated with inhibition of ovulation~      * oral~     * injectable~     * implantable~  3. intrauterine device (IUD)~  4. intrauterine hormone-releasing system (IUS)~  5. bilateral tubal occlusion~  6. total abstinence or vasectomized partner.~Exclusion Criteria:~1. Inability to provide informed consent~2. Patients with body mass index (BMI) \> 30, or weight \>100 kg~3. Patients with weight \<50 kg~4. Patients with unstable cardiovascular status incl. NYHA class III/IV or symptoms of angina pectoris.~5. Patients with uncontrolled hypertension (≥160/105 mmHg).~6. Patients with active on-going infections.~7. Patients with latent or previous as well as on-going therapy against tuberculosis, or exposed to tuberculosis or has travelled in areas with high risk of tuberculosis or mycosis within the last 3 months.~8. Patients with serological evidence of infection with HIV, Treponema pallidum, hepatitis B antigen (patients with serology consistent with previous vaccination and a history of vaccination are acceptable) or hepatitis C.~9. Patients with any immune suppressive treatment~10. Patients with known demyelinating disease or with symptoms or physical examination findings consistent with possible demyelinating disease-~11. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.~12. Patients with known, or previous, malignancy.~13. Taking oral anti-diabetic therapies or any other concomitant medication which may interfere with glucose regulation other than insulin.~14. Patients with GFR \<80 ml/min/1.73 m2 body surface.~15. Patients with proliferative retinopathy.~16. Patient with any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo treatment with MSC.~17. Known hypersensitivity against any excipients, i.e. dimethyl sulfoxide (DMSO).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Allogeneic transplantation with WJMSCs (Type: EXPERIMENTAL): Single infusion of 200 million cells per patient.
- Sham transplantation (placebo) (Type: PLACEBO_COMPARATOR): Single infusion with albumin and dmso in sodium chloride (identical concentrations as active treatment)

Based on this trial design, predict the completion outcome and termination type (if applicable).